drugset / Trial / NCT05043675

Clinical Evaluation of [18F]APN-1607 PET Uptake in Alzheimer's Disease Patients

NCT05043675

NaSingle-groupOpen-labelOther

Summary

The overall objective of this study is to evaluate the overall pattern of \[18F\]APN-1607 uptake in subjects with AD dementia

Timeline

Start
2021-09-10
Primary completion
2024-09-10
Completion
2024-09-10

Drugs

EvaluationDrugModalityDoseRoute
Subject [18F]APN-1607 Diagnostic / imaging agent 3.7 mbq/kg Other
Subject [18F]APN-1607 Diagnostic / imaging agent 5.55 mbq/kg Other

Indications